• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Preventive Medicine Reports >Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population
【2h】

Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population

机译：高危人群中宫颈癌筛查的依从性因人乳头瘤病毒疫苗的接种状况而异

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cervical cancer screening has reduced the incidence of cervical cancer over the past 75 years. The primary aim of this study was to determine if women receiving Gardasil™ (HPV4 vaccine) participated in future cervical cancer screening at the same rate as that observed for unvaccinated women matched on birth year and health care campus. This is a retrospective cohort study of subjects selected from 27,786 females born from 1980 to 1992 who received health care in the Truman Medical Center safety net health system in Kansas City Missouri, USA. 1154 women 14–26 years old who received at least one dose of HPV4 vaccine between 2006 and 2009 were chosen at random from the vaccine records. 1154 randomly chosen unvaccinated women were age and health campus matched to the vaccinated women and all were followed until July 1, 2013. Women who were screened after 21 years and received three vaccine doses before 21 years, had the lowest screening rate of 24%. Their only predictive factor for screening, compared to the unvaccinated, was being closer to 21 years than 14 years at vaccination (aOR = 1.71 95% CI: 1.45, 2.00). Women vaccinated with three doses and screened at or after 21 years had the highest screening rate of 84% predicting a six-fold increase in screening participation over no vaccine received (aOR = 5.94 95% CI: 3.77, 9.35). Our results suggest that women who receive HPV4 vaccination closer to 21 years, not 14, are more likely to participate in cervical cancer screening in an underserved US population.
机译：在过去的75年中，宫颈癌筛查降低了宫颈癌的发病率。这项研究的主要目的是确定接受Gardasil™（HPV4疫苗）的妇女是否以与出生年份和医疗园区相匹配的未接种疫苗的妇女相同的比率参加以后的宫颈癌筛查。这是一项回顾性队列研究，研究对象是从1980年至1992年出生的27786名女性，这些女性在美国密苏里州堪萨斯城的杜鲁门医疗中心安全网卫生系统中接受过卫生保健。从疫苗记录中随机选择1154名14-26岁的妇女，他们在2006年至2009年之间接受了至少一剂HPV4疫苗。随机选择了1154名未接种疫苗的妇女，这些妇女的年龄和健康状况与接种疫苗的妇女相匹配，所有患者均被随访至2013年7月1日。在21岁之后接受筛查并在21岁之前接受过三剂疫苗的女性筛查率最低，为24％。与未接种疫苗相比，他们唯一的筛查预测因素是接种疫苗后14年比21岁（aOR = 1.71 95％CI：1.45，2.00）。接受三剂疫苗接种并在21岁或之后接受筛查的妇女的最高筛查率为84％，预计筛查参与率是未接种疫苗的六倍（aOR = 5.94 95％CI：3.77，9.35）。我们的结果表明，在未得到充分服务的美国人群中，接受HPV4疫苗接种接近21年而不是14岁的女性更有可能参与宫颈癌筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号